Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
| ▸ | TGM2 | P21980 | 8/20 | 0.41 |
| ▸ | F13A1 | P00488 | 7/20 | 0.41 |
| ▸ | TGM1 | P22735 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.41 |
| ▸ | KRAS | P01116 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | USP7 | Q93009 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12259618 | 0.97 | FPR2 (0.41) | FPR2TGM2F13A1TGM1ALDH1A1 | |
| SCHEMBL1722727 | 0.87 | ALDH1A1 (0.42) | ALDH1A1TSHRMAPTLMNAMEN1 | |
| SCHEMBL12259612 | 0.85 | DRD2 (0.42) | MAPTEPHX2LMNA | |
| SCHEMBL12259613 | 0.84 | JAK2 (0.39) | FPR2ALDH1A1TSHRMAPTLMNA | |
| SCHEMBL2395625 | 0.83 | ALDH1A1 (0.40) | ALDH1A1TSHRMAPTEPHX2LMNA | |
| SCHEMBL2392681 | 0.79 | MAPT (0.41) | ALDH1A1TSHRMAPTLMNAMEN1 | |
| SCHEMBL2393024 | 0.79 | MAPT (0.43) | ALDH1A1TSHRMAPTEPHX2LMNA | |
| SCHEMBL2392677 | 0.79 | MAPT (0.43) | ALDH1A1TSHRMAPTEPHX2LMNA | |
| SCHEMBL2390183 | 0.78 | TGM2 (0.36) | TGM2F13A1TGM1TGM3KRAS | |
| SCHEMBL2394029 | 0.77 | TGM2 (0.36) | TGM2F13A1TGM1TGM3KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012980-B2 | Isoquinolinone derivatives | ASTRAZENECA AB (SE) | 2011-09-06 | — | — | US | disclosed |
| EP-2344472-A1 | ISOQUINOLINONE DERIVATIVES | AstraZeneca AB (SE) | 2011-07-20 | — | — | EP | disclosed |
| US-20100099665-A1 | ISOQUINOLINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | US | disclosed |
| WO-2010039079-A1 | ISOQUINOLINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099665-A1 | ISOQUINOLINONE DERIVATIVES | SDHA, NQO1, CYP3A5 | FPR2 1636/4885TGM2 1801/4885F13A1 3933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.